Vive la difference: Sex and fluorouracil toxicity

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1439-1441

  Macdonald, John S ^a  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ALOPECIA; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COLORECTAL CARCINOMA; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; EDITORIAL; HUMAN; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; SEXUAL FUNCTION; STOMATITIS; VOMITING;

EID: 0037087667     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.6.1439     Document Type: Editorial

References (12)

1. Cancer statistics
2. Adjuvant therapy of colon cancer
3. Irinotecan plus fluorouracil and leucovorin for metastatic colon cancer
4. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
5. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer
6. ERCC1 and thymidylate synthase m-RNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
7. Dihydropyrimidine dehydrogenase: Its role in 5-flouorouracil clinical toxicity and tumor resistance
8. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promotor may predict downstaging after preoperative chemoradiation in rectal cancer
9. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
10. Human thymidylate synthase gene polymorphism determines response to 5-FU chemotherapy
11. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study
12. Fluorouracil modulation in colorectal cancer: Lack of improvement with N-phophonoacetyl-1-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24 hour infusion schedule - An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B study